Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Photon DR

This article was originally published in The Gray Sheet

Executive Summary

Dual-chamber, rate responsive, implantable cardioverter defibrillator premarket approval application is submitted to FDA, the firm reports June 14. The 46 cc tachycardia device offers 37 J of stored energy and incorporates Affinity pacemaker technology for treatment of bradycardia as well (1"The Gray Sheet" Feb. 14, p. 12). Approval of the device, "the world's thinnest dual-chamber ICD" at 12.7 mm, is anticipated later this year. St. Jude is counting on the Photon to wrest ICD market share from market leaders Medtronic and Guidant

You may also be interested in...



St. Jude Photon ICD PMA Submission Expected By Mid-Year

St. Jude Medical says it expects to file a premarket approval application with FDA for the Photon DR dual-chamber implantable cardioverter defibrillator by mid-year.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

MT013527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel